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Editorial on the Research Topic
Exploiting DNA Damage Response in the Era of Precision Oncology
The main scope of precision oncology is providing a personally tailored cancer treatment that
targets specific driver alterations identified via a next generation sequencing profiling of a patient
tumor. The application of precision oncology is evolving dramatically and is constantly reshaping
cancer treatment. The already routine implementation of trastuzumab and pertuzumab for
treatment of breast cancer patients with HER2/neu amplification, imatinib in chronic myeloid
leukemia and gastrointenstinal stromal tumors, dabrafenib and trametinib in BRAFV600E-mutant
melanoma, erlotinib and crizotinib for non-small cell lung cancer with the EGFR p.L858R mutation
or the ALK/EML4 rearrangement, respectively, serve as only few examples for the proof of
principle (1).
Genome stability is critical for the maintenance of cellular physiology and is persistently
sustained by the complex signaling networks of cell cycle checkpoint mediators and DNA repair
effectors that together constitute the DNA damage response (DDR) network, which monitors and
repairs damaged DNA (2–4). A major consequence of a compromised DDR function is cellular
transformation and the onset and progression of cancer. Indeed, genomic instability is recognized as
a major hallmark of cancer that commonly evolves on a defective DDR function background (5).
Targeting specific DDR signaling pathways in the context of precision oncology offers
opportunities on two different, but complementary levels. Firstly, the vast majority of anti-cancer
conventional approaches that consist of radiation therapy, as well as chemotherapeutic drugs as for
example platinum compounds, topoisomerase inhibitors and temozolomide, elicit their cytotoxicity
via DNA damage. Deregulated upregulation of particular DDR pathways by cancer cells may
provide an escape mechanism that results in more efficient DNA repair with consequent treatment
resistance and less favorable prognosis (6). Depending on a particular tumor landscape, a
personalized targeted intervention within a specific relevant DDR pathway may therefore be
instrumental for overcoming treatment resistance via chemo-radiosensitization. In that respect,
effective and specific targeting of the three DDR master upstream kinases of the PIKK family, ATM,
ATR and DNA-PK, is in the center of major research efforts in the last years (7–9). An additional
targeting concept to effectively induce tumor cell death is blocking of cell cycle checkpoint
mediators, such as CHK1, CHK2, and WEE1 in cancer cells with a high replication stress,
allowing therefore cell cycle progression with a high burden of DNA damage (10).October 2020 | Volume 10 | Article 6111271
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personalized cancer treatment are tumors with loss-of-function
mutations in genes encoding DDR components of a particular
repair pathway. These mutations may create an ultimate
dependency on an alternative pathway, which, if targetable,
creates a tumor-specific vulnerability in the form of a synthetic
lethal interaction exploitable in the clinic. Obviously, the dogma
of targeting synthetic lethal interactions in the context of DDR
signaling has been established through the integration of PARP
inhibitors in the management of homologous recombination-
deficient tumors due to BRCA1/BRCA2 inactivating mutations
(11–15). Motivated by this successful clinical implementation,
functional genomic screens are profoundly used to identify novel
synthetic interactions and drug targets in human cancers (16).
This Research Topic of Frontiers in Oncology entitled
“Exploiting DNA Damage Response in the Era of Precision
Oncology” aimed at bringing together contributions covering
various aspects of DDR targeting in the context of precision
oncology frameworks. The scopes of the research and review
articles included in this collection are described below:
- Mohiuddin andKang discuss in their review the biologic rationale
for DNA-PK as a target in cancer. The roles of DNA-PK within
the DDR, as well as in non-DDR signaling are described and an
updated overview over the pharmacological efforts for
generating effective inhibitors is provided.
- In the original research article by Lundgren Mortensen et al. the
authors explore a tumor radiosensitization approach, which
aims at increasing cellular p53 levels by using a stapled peptide,
PM2, that interferes with the MDM2/X-dependent p53
downregulation. The effectiveness of PM2 together with
external beam radiotherapy has been investigated in a panel of
cancer cells.
- Das et al. have presented data of a computational approach to
predict synthetic lethal interactions of somatic mutations in
DDR genes within a TCGA-based pan-cancer cohort of
patients. They have used various in silico approaches,
including drug sensitivities responses, to validate the novel
described synthetic lethal interactions.
- Carr et al. investigated in their research on acute myeloid
leukemia a combination of the novel DNA-PK inhibitor
M3814 and Mylotarg, an approved CD33 antibody
conjugated with the DNA double strand break-inducing
drug calicheamicin. The study demonstrated an enhancedFrontiers in Oncology | www.frontiersin.org 2anti-tumor activity of Mylotarg in the combined treatment
modality, resulting from the inhibition of the DNA double
strand break repair through non-homologous end-joining via
M3814.
- Baldwin et al. explored the efficacy of a nano-formulation of the
PARP inhibitor talazoparib in combination with
temozolomide in xenograft models of Ewing Sarcoma. Their
data suggest that the nanoparticle formulation of talazoparib
reduces the toxicity of the combined treatment as compared
to oral administration of the PARP inhibitor.
- Meng et al. reviewed the signaling interplay between DDR
pathways, RNA processing and the generation of tumor-
associated extracellular vesicles that are linked to treatment
resistance and metastasis.
- The minireview by Trenner and Sartori focused on most recent
updates concerning DNA double strand breaks repair
pathways and how they could be exploited further for
cancer treatment. Particular emphasis of this work is on
combinatorial therapeutic approaches and the targeting of
potentially newly discovered synthetic lethal interactions.
- Liptay et al. reviewed mechanisms of acquired drug resistance
in tumors with DDR deficiencies. The authors of this study
concentrated primarily on BRCA-deficient cancers and the
emerging role of replication fork biology in acquired drug
resistance in these tumors.
- Burgess et al. reviewed mechanisms involved in genomic
instability of lung tumors and therapeutic opportunities in
combination of DDR-based targeting with various modalities
including immunotherapies.
Our understanding of the intricate and extremely complex
network of the cellular DDR reshaped by groundbreaking
discoveries in the last decades allowed numerous successful
implementations of these findings into clinical practice. At the
same time, the more we know, the more new questions arise. To
one of them – who will profit from a specific therapy? –precision
oncology will have to furnish answers all over again and again.AUTHOR CONTRIBUTIONS
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